The Pentagon has issued new guidance mandating testosterone testing for male service members aged 30 and older, following a brief pause after the original policy was published and withdrawn. The updated directive, released late Thursday, excludes female personnel for the time being, citing medical experts’ concerns about the necessity and efficacy of such a program.
Defense Secretary Pete Hegseth announced in July that a broad screening program for “testosterone deficiency” would be rolled out to help troops operate at their “absolute best.” The clinical guidance outlines how the mandatory tests will be conducted and notes that the female clinical practice guideline is under review, with no current requirement for routine hormonal testing for women.
The policy departs from standard medical recommendations, which advise testing only men who report specific symptoms such as low libido or depressed mood, and requires two confirmatory blood tests. Instead, the Pentagon will test every eligible male, while allowing younger personnel to request testing. The guidance acknowledges the limited benefits of hormone replacement, stating that evidence does not support its use to improve energy or cognition, but cites demonstrated benefits for sexual function and bone density.
The memo also warns of potential side effects, including a reduction in sperm count, and instructs providers not to prescribe testosterone for those planning to father children soon. It outlines logistical challenges for deployment, noting that injectable testosterone requires controlled room‑temperature storage and strict accountability, and that supply issues must be resolved before deployment rather than in theater. This contrasts with Hegseth’s July remarks that testosterone therapy is part of ensuring maximum psychological and mental readiness on the modern battlefield.
